bio sketch column
Ellen L. Berg, PhD, is Chief Scientific Officer for BioMAP Systems at DiscoverX Corporation and responsible for the company’s BioMAP® platform of human primary cell based assays and predictive analysis tools. Dr. Berg was a founder and CSO of BioSeek, acquired by DiscoverX in 2012, and previously led a research team at Protein Design Labs, developing novel therapeutic antibodies for inflammatory diseases. She received her PhD from Northwestern University, studying mechanisms of antigen presentation and immune responses. Dr. Berg was a postdoctoral fellow at Stanford University in the Department of Pathology, where she was a fellow of the American Cancer Society and a Special Fellow of the Leukemia Society of America. Her postdoctoral work led to the discovery of adhesion receptors involved in leukocyte recruitment into tissues and sites of inflammation. Dr. Berg is an expert in in vitro models of human disease and tissue biology, holds a number of patents in the field of inflammation, and has authored over 75 publications. She has served in various positions with the Society of Laboratory Automation and Screening, is a member of the Society of Toxicology and a board member of the American Society for Cellular and Computational Toxicology. Her research interests include systems biology, chemical biology, drug and toxicity mechanisms of action, phenotypic drug discovery, alternative methods for animal use, and predictive methods for human efficacy and safety outcomes.